

Resource Summary Report

Generated by ASWG on Aug 9, 2026

PerCP/Cyanine5.5 anti-human CD8

RRID:AB_2044010

Type: Antibody

Proper Citation

BioLegend Cat# 344710, RRID:AB_2044010

Antibody Information

URL: http://antibodyregistry.org/AB_2044010

Proper Citation: BioLegend Cat# 344710, RRID:AB_2044010

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2044010

Vendor: BioLegend

Catalog Number: 344710

Alternative Catalog Numbers: 344709

Record Creation Time: 20250820T003100+0000

Record Last Update: 20250820T082836+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD8.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Podaza E, et al. (2026) Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. *Cell reports methods*, 6(6), 101339.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1557.

Wang Y, et al. (2026) Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4+ T cell help. *Cell reports methods*, 101533.

Cheng Z, et al. (2026) Structural dissection of CD38 antigen engagement by CAR binders and rational affinity tuning. *iScience*, 29(6), 115937.

Chi H, et al. (2025) SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint That Enables Tumor Immune Evasion by Impairing T-cell Cytotoxicity. *Cancer research*, 85(5), 912.

Huang F, et al. (2025) Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. *Cancer cell*, 43(8), 1460.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Forconi CS, et al. (2025) T follicular helper cell profiles differ by malaria antigen and for children compared to adults. *bioRxiv : the preprint server for biology*.

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. *Cell reports. Medicine*, 6(8), 102252.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. *Cell reports. Medicine*, 6(2), 101967.

Forconi CS, et al. (2025) T-follicular helper cell profiles differ by malaria antigen and for children compared to adults. *eLife*, 13.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. *Cell reports. Medicine*, 6(12), 102466.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. *Cell reports. Medicine*, 5(6), 101585.

Shin OS, et al. (2024) Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38. *Cell reports*, 43(7), 114502.

Rubino V, et al. (2024) IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. *Cell reports. Medicine*, 5(11), 101826.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. *Cell reports. Medicine*, 5(3), 101448.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Pai JA, et al. (2023) Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. *Cancer cell*, 41(4), 776.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.